Literature DB >> 12368361

Evidence for regulation of long terminal repeat transcription by Wnt transcription factor TCF-4 in human astrocytic cells.

Bethany Wortman1, Nune Darbinian, Bassel E Sawaya, Kamel Khalili, Shohreh Amini.   

Abstract

The Wnt signaling pathway plays an important role in neural cell development and function. The key components of this pathway, beta-catenin and its partner TCF-4/LEF-1, exert their effects on transcription by entering the nuclei, where they associate with the TCF-4/LEF-1 DNA motif positioned in the promoters of several important genes. Here we examined the role of TCF-4 upon transcription of the human immunodeficiency virus type 1 (HIV-1) promoter in human astrocytic cells. Our results showed that expression of TCF-4 in human astrocytic cells (U-87MG cells) decreased the basal and Tat-mediated transcription of the HIV-1 long terminal repeat (LTR). Results from promoter deletion studies revealed that the promoter sequence of the LTR with no classical binding motif for TCF-4/LEF-1, which spans positions -80 to +80 of the LTR, remained responsive to down-regulation by TCF-4. Noticeably, removal of the sequences between positions -80 and -68 decreased the negative effect of TCF-4 on viral gene transcription. A mutant variant of TCF-4 with no binding site for beta-catenin was able to down-regulate LTR transcription, suggesting that beta-catenin may not be directly involved in the observed regulatory events. Results from the glutathione S-transferase pull-down assay as well as the combined immunoprecipitation and Western blot analysis of protein extract from U-87MG cells revealed an interaction of Tat with TCF-4. Subcellular examination of TCF-4 and Tat in cells expressing either protein alone showed a predominantly nuclear accumulation of these proteins. However, in cells which coexpressed both TCF-4 and Tat, significant levels of these proteins were found in the cytoplasm. All together, these observations provide evidence for the cooperative interaction of TCF-4, the important transcription factor of the Wnt pathway, with Tat; this interaction may determine the level of viral gene transcription in human astrocytic cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368361      PMCID: PMC136655          DOI: 10.1128/jvi.76.21.11159-11165.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer.

Authors:  K Hovanes; T W Li; J E Munguia; T Truong; T Milovanovic; J Lawrence Marsh; R F Holcombe; M L Waterman
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

2.  The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.

Authors:  T P Cujec; H Okamoto; K Fujinaga; J Meyer; H Chamberlin; D O Morgan; B M Peterlin
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

Review 3.  Signal transduction through beta-catenin and specification of cell fate during embryogenesis.

Authors:  J R Miller; R T Moon
Journal:  Genes Dev       Date:  1996-10-15       Impact factor: 11.361

Review 4.  TCF/LEF factor earn their wings.

Authors:  H Clevers; M van de Wetering
Journal:  Trends Genet       Date:  1997-12       Impact factor: 11.639

5.  Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase.

Authors:  S Kumar; M J Orsini; J C Lee; P C McDonnell; C Debouck; P R Young
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

6.  Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates TAR-independent transactivation by Tat.

Authors:  J P Taylor; R J Pomerantz; G V Raj; F Kashanchi; J N Brady; S Amini; K Khalili
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

8.  Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro.

Authors:  P L Sheridan; C T Sheline; K Cannon; M L Voz; M J Pazin; J T Kadonaga; K A Jones
Journal:  Genes Dev       Date:  1995-09-01       Impact factor: 11.361

9.  Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development.

Authors:  V Brault; R Moore; S Kutsch; M Ishibashi; D H Rowitch; A P McMahon; L Sommer; O Boussadia; R Kemler
Journal:  Development       Date:  2001-04       Impact factor: 6.868

10.  TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation.

Authors:  J P Taylor; R Pomerantz; O Bagasra; M Chowdhury; J Rappaport; K Khalili; S Amini
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  24 in total

1.  Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Authors:  Kylene Kehn-Hall; Irene Guendel; Lawrence Carpio; Leandros Skaltsounis; Laurent Meijer; Lena Al-Harthi; Joseph P Steiner; Avindra Nath; Olaf Kutsch; Fatah Kashanchi
Journal:  Virology       Date:  2011-04-22       Impact factor: 3.616

Review 2.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 3.  Targeting Wnt pathways in disease.

Authors:  Zachary F Zimmerman; Randall T Moon; Andy J Chien
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

4.  IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner.

Authors:  Wei Li; Lisa J Henderson; Eugene O Major; Lena Al-Harthi
Journal:  J Immunol       Date:  2011-05-11       Impact factor: 5.422

5.  β-Catenin/TCF-4 signaling regulates susceptibility of macrophages and resistance of monocytes to HIV-1 productive infection.

Authors:  Yosra Aljawai; Maureen H Richards; Melanie S Seaton; Srinivas D Narasipura; Lena Al-Harthi
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

6.  Dynamic interaction between astrocytes and infiltrating PBMCs in context of neuroAIDS.

Authors:  Maureen H Richards; Srinivas D Narasipura; Stephanie Kim; Melanie S Seaton; Victoria Lutgen; Lena Al-Harthi
Journal:  Glia       Date:  2014-10-21       Impact factor: 7.452

Review 7.  Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.

Authors:  Jean-François Gélinas; Deborah R Gill; Stephen C Hyde
Journal:  Microbiol Mol Biol Rev       Date:  2018-01-10       Impact factor: 11.056

8.  Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis.

Authors:  Madhav C Menon; Peter Y Chuang; Zhengzhe Li; Chengguo Wei; Weijia Zhang; Yi Luan; Zhengzi Yi; Huabao Xiong; Christopher Woytovich; Ilana Greene; Jessica Overbey; Ivy Rosales; Emilia Bagiella; Rong Chen; Meng Ma; Li Li; Wei Ding; Arjang Djamali; Millagros Saminego; Philip J O'Connell; Lorenzo Gallon; Robert Colvin; Bernd Schroppel; John Cijiang He; Barbara Murphy
Journal:  J Clin Invest       Date:  2014-12-01       Impact factor: 14.808

Review 9.  Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS.

Authors:  Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

10.  Human immunodeficiency virus-restricted replication in astrocytes and the ability of gamma interferon to modulate this restriction are regulated by a downstream effector of the Wnt signaling pathway.

Authors:  Deborah Carroll-Anzinger; Anvita Kumar; Vyacheslav Adarichev; Fatah Kashanchi; Lena Al-Harthi
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.